DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

Multiple Trials Underway

 
• By Dexter Jie Yan
  
Dualtiy and BioNTech bet on the novel combo of ADC and PD-L1/VEGF-A-targeting bispecific antibody. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D